Connect your AI

Opus Genetics IRD Total Liabilities

Total Liabilities at other companies

MeiraGTx Holdings plcMGTX

$302.79M+58.6%

4D Molecular TherapeuticsFDMT

$61.07M+32.7%

Opko HealthOPK

$652.19M-20.1%

Kodiak Sciences IncKOD

$193.91M+2.6%

Regeneron PharmaceuticalsREGN

$9.45B+15.8%

RegenxbioRGNX

$320.81M+48.0%

Other financials

Income statement

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

Operating cash flow-$12.7M-41.5%

Valuation

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Opus Genetics's total liabilities?: Opus Genetics (IRD) reported total liabilities of $77.35M in Q1 2026.
How has Opus Genetics's total liabilities changed year-over-year?: Opus Genetics's total liabilities increased by 219.0% year-over-year, from $24.25M to $77.35M.
What is the long-term trend for Opus Genetics's total liabilities?: Over 5 years (2020 to 2025), Opus Genetics's total liabilities has grown at a -3.6% compound annual growth rate (CAGR), from $31.15M to $25.99M.
What does total liabilities mean?: The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.